{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:36:49Z","timestamp":1782765409677,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"UCB Pharma, Taipei, Taiwan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00619-4","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T18:01:59Z","timestamp":1714240919000},"page":"809-824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Epidemiology, Patient Characteristics, and Treatment Patterns of Myasthenia Gravis in Taiwan: A Population-Based Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Nai-Wen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Nien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Shan","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Pei","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Horng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"issue":"1","key":"619_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516.","journal-title":"J Transl Med"},{"issue":"11","key":"619_CR2","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","volume":"264","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang S, Xi J, et al. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2017;264(11):2191\u2013200.","journal-title":"J Neurol"},{"key":"619_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.12688\/f1000research.8206.1","volume":"5","author":"WD Phillips","year":"2016","unstructured":"Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:1513.","journal-title":"F1000Res"},{"issue":"3","key":"619_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","volume":"45","author":"JT Guptill","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve. 2012;45(3):363\u20136.","journal-title":"Muscle Nerve"},{"key":"619_CR5","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"619_CR6","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269(6):3050\u201363.","journal-title":"J Neurol"},{"issue":"6","key":"619_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","volume":"33","author":"IZ Basta","year":"2012","unstructured":"Basta IZ, Pekmezovi\u0107 TD, Peri\u0107 SZ, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci. 2012;33(6):1375\u201381.","journal-title":"Neurol Sci"},{"issue":"4","key":"619_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000328863","volume":"36","author":"F Pallaver","year":"2011","unstructured":"Pallaver F, Riviera AP, Piffer S, et al. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011;36(4):282\u20137.","journal-title":"Neuroepidemiology"},{"issue":"1\u20132","key":"619_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305(1\u20132):97\u2013102.","journal-title":"J Neurol Sci"},{"key":"619_CR10","doi-asserted-by":"publisher","first-page":"1203679","DOI":"10.3389\/fneur.2023.1203679","volume":"14","author":"KJ Herr","year":"2023","unstructured":"Herr KJ, Shen SP, Liu Y, Yang CC, Tang CH. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. Front Neurol. 2023;14:1203679.","journal-title":"Front Neurol"},{"issue":"4","key":"619_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","volume":"33","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord. 2023;33(4):324\u201333.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"619_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000279334","volume":"34","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171\u201383.","journal-title":"Neuroepidemiology"},{"issue":"3","key":"619_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3988\/jcn.2016.12.3.340","volume":"12","author":"SY Park","year":"2016","unstructured":"Park SY, Lee JY, Lim NG, Hong YH. Incidence and prevalence of myasthenia gravis in Korea: a population-based study using the national health insurance claims database. J Clin Neurol. 2016;12(3):340\u20134.","journal-title":"J Clin Neurol"},{"issue":"5","key":"619_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10072-019-04146-1","volume":"41","author":"W Fang","year":"2020","unstructured":"Fang W, Li Y, Mo R, et al. Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China. Neurol Sci. 2020;41(5):1211\u201323.","journal-title":"Neurol Sci"},{"issue":"1","key":"619_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","volume":"35","author":"CH Lai","year":"2010","unstructured":"Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010;35(1):66\u201371.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"619_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328.","journal-title":"Neurol Ther"},{"issue":"1","key":"619_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023;68(1):8\u201319.","journal-title":"Muscle Nerve"},{"issue":"1","key":"619_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation. 2022;19(1):89.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"619_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"619_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of british neurologists\u2019 management guidelines. Pract Neurol. 2015;15(3):199\u2013206.","journal-title":"Pract Neurol"},{"key":"619_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"issue":"11","key":"619_CR22","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1111\/trf.14915","volume":"58","author":"GY Hung","year":"2018","unstructured":"Hung GY, Lee CY, Yen HJ, Lin LY, Horng JL. Incidence of immune thrombocytopenia in Taiwan: a nationwide population-based study. Transfusion. 2018;58(11):2712\u20139.","journal-title":"Transfusion"},{"key":"619_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"619_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7\u201316.","journal-title":"J Med Life"},{"issue":"9251","key":"619_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(05)71337-4","volume":"357","author":"K Poulas","year":"2001","unstructured":"Poulas K, Tzartos SJ. The gender gap in autoimmune disease. Lancet. 2001;357(9251):234.","journal-title":"Lancet"},{"issue":"4","key":"619_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.nmd.2023.02.013","volume":"33","author":"YL Tang","year":"2023","unstructured":"Tang YL, Ruan Z, Su Y, et al. Clinical characteristics and prognosis of very late-onset myasthenia gravis in China. Neuromuscul Disord. 2023;33(4):358\u201366.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"619_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","volume":"56","author":"JA Aarli","year":"1999","unstructured":"Aarli JA. Late-onset myasthenia gravis: a changing scene. Arch Neurol. 1999;56(1):25\u20137.","journal-title":"Arch Neurol"},{"issue":"6","key":"619_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4103\/ijp.IJP_452_17","volume":"50","author":"R Bansal","year":"2018","unstructured":"Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Indian J Pharmacol. 2018;50(6):302\u20138.","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"619_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, Chong MK, Wu Y, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"619_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12883-023-03406-0","volume":"23","author":"H Wilcke","year":"2023","unstructured":"Wilcke H, Glaubitz S, K\u00fcck F, et al. Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study. BMC Neurol. 2023;23(1):366.","journal-title":"BMC Neurol"},{"issue":"9","key":"619_CR31","volume":"12","author":"S Amin","year":"2020","unstructured":"Amin S, Aung M, Gandhi FR, Pena Escobar JA, Gulraiz A, Malik BH. Myasthenia gravis and its association with thyroid diseases. Cureus. 2020;12(9):e10248.","journal-title":"Cureus"},{"key":"619_CR32","volume":"2011","author":"F Romi","year":"2011","unstructured":"Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis. 2011;2011:474512.","journal-title":"Autoimmune Dis"},{"issue":"4","key":"619_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.27791","volume":"67","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: a United States health claims analysis. Muscle Nerve. 2023;67(4):297\u2013305.","journal-title":"Muscle Nerve"},{"issue":"3","key":"619_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. international consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"1","key":"619_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/mus.26719","volume":"61","author":"MH Alanazy","year":"2020","unstructured":"Alanazy MH, Binabbad RS, Alromaih NI, et al. Severity and depression can impact quality of life in patients with myasthenia gravis. Muscle Nerve. 2020;61(1):69\u201373.","journal-title":"Muscle Nerve"},{"key":"619_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06767.x","volume":"1275","author":"V Bril","year":"2012","unstructured":"Bril V, Barnett-Tapia C, Barth D, Katzberg HD. IVIG and PLEX in the treatment of myasthenia gravis. Ann N Y Acad Sci. 2012;1275:1\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"619_CR37","first-page":"419","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Exec Summ. 2016;87(4):419\u201325.","journal-title":"Exec Summ"},{"key":"619_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/NDT.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza R, Bonanno S, Camera G, Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011;7:151\u201360.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"619_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/ane.12374","volume":"132","author":"JH Yeh","year":"2015","unstructured":"Yeh JH, Chen HJ, Lin CC, Chen YK, Chiu HC, Kao CH. Risk of diabetes mellitus among patients with myasthenia gravis. Acta Neurol Scand. 2015;132(2):132\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"619_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322.","journal-title":"Neurohospitalist"},{"issue":"1","key":"619_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1):e000241.","journal-title":"BMJ Med"},{"key":"619_CR42","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020;11:604.","journal-title":"Front Neurol"},{"issue":"6","key":"619_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, et al. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023;94(6):467\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"619_CR44","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314\u201320.","journal-title":"J Neurol"},{"issue":"1","key":"619_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13760-019-01209-0","volume":"120","author":"BK Vitturi","year":"2020","unstructured":"Vitturi BK, Pellegrinelli A, Valerio BCO. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study. Acta Neurol Belg. 2020;120(1):83\u20139.","journal-title":"Acta Neurol Belg"},{"key":"619_CR46","doi-asserted-by":"publisher","first-page":"1214041","DOI":"10.3389\/fneur.2023.1214041","volume":"14","author":"T Sobierajski","year":"2023","unstructured":"Sobierajski T, Lasek-Bal A, Krzystanek M, Gilhus NE. Diagnosis and therapy of myasthenia gravis-the patients\u2019 perspective: a cross-sectional study. Front Neurol. 2023;14:1214041.","journal-title":"Front Neurol"},{"key":"619_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8497","volume":"345","author":"J Spillane","year":"2012","unstructured":"Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ. 2012;345: e8497.","journal-title":"BMJ"},{"issue":"15","key":"619_CR48","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.293.15.1906","volume":"293","author":"K Scherer","year":"2005","unstructured":"Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA. 2005;293(15):1906\u201314.","journal-title":"JAMA"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00619-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:34:35Z","timestamp":1716968075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00619-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00619-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Connie Hung and Amanda Kuo are employees of UCB Pharma. Hung-Wei Lin, and Kai-Pei Chou are employees of IQVIA Solutions Taiwan Ltd. Li-Shan Jian is a former employee of IQVIA Solutions Taiwan Ltd., and the work was done while affiliated with IQVIA Solutions Taiwan Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Taipei Medical University (Approval number N202203018). Informed consent was waived because of the study\u2019s descriptive and non-interventional nature, and the analysis was de-identified. This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}